| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Markus Tolnay | Q47157920 |
| P2093 | author name string | Michel Goedert | |
| Florence Clavaguera | |||
| Markus Tolnay | |||
| P433 | issue | 7 | |
| P921 | main subject | prion protein family | Q24724413 |
| neurodegeneration | Q1755122 | ||
| P304 | page(s) | 317-325 | |
| P577 | publication date | 2010-05-20 | |
| P1433 | published in | Trends in Neurosciences | Q3538443 |
| P1476 | title | The propagation of prion-like protein inclusions in neurodegenerative diseases | |
| P478 | volume | 33 |
| Q38099071 | "Prion-like" templated misfolding in tauopathies |
| Q48278741 | 100 years of Lewy pathology |
| Q34616539 | A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity |
| Q41069719 | A novel panel of α-synuclein antibodies reveal distinctive staining profiles in synucleinopathies. |
| Q28393872 | A quantitative study of tau pathology in eleven cases of chronic traumatic encephalopathy |
| Q33698975 | A quantitative study of α-synuclein pathology in fifteen cases of dementia associated with Parkinson disease |
| Q51247399 | A two population model of prion transport through a tunnelling nanotube. |
| Q42246480 | Aggregation and neurotoxicity of recombinant α-synuclein aggregates initiated by dimerization |
| Q35079415 | Alpha-synuclein transfers from neurons to oligodendrocytes |
| Q30415581 | Alzheimer disease: a tale of two prions |
| Q47783009 | Alzheimer's Disease: Characterization of the Brain Sites of the Initial Tau Cytoskeletal Pathology Will Improve the Success of Novel Immunological Anti-Tau Treatment Approaches |
| Q28250275 | Alzheimer's disease and prion protein |
| Q37868480 | Alzheimer's pathogenesis: is there neuron-to-neuron propagation? |
| Q90673210 | Amyloid fibril structure of α-synuclein determined by cryo-electron microscopy |
| Q28742804 | Amyloid oligomer neurotoxicity, calcium dysregulation, and lipid rafts |
| Q36496566 | Aneuploidy causes proteotoxic stress in yeast |
| Q37789524 | Are synucleinopathies prion-like disorders? |
| Q57289144 | Attempt to Untangle the Prion-Like Misfolding Mechanism for Neurodegenerative Diseases |
| Q26765999 | Beta-Amyloid and Tau-Protein: Structure, Interaction, and Prion-Like Properties |
| Q36465091 | Biochemical classification of tauopathies by immunoblot, protein sequence and mass spectrometric analyses of sarkosyl-insoluble and trypsin-resistant tau |
| Q38023859 | Biochemistry and cell biology of tau protein in neurofibrillary degeneration |
| Q38060618 | Bioinformatics aggregation predictors in the study of protein conformational diseases of the human nervous system |
| Q36915421 | Brain homogenates from human tauopathies induce tau inclusions in mouse brain |
| Q37212178 | Brain site-specific proteome changes in aging-related dementia |
| Q57801618 | Brain structural alterations are distributed following functional, anatomic and genetic connectivity |
| Q37650426 | Brain-derived neurotrophic factor protects against tau-related neurodegeneration of Alzheimer's disease |
| Q38196398 | Cannabinoids for treatment of Alzheimer's disease: moving toward the clinic. |
| Q44297524 | Cell transplantation and gene therapy in Parkinson's disease |
| Q36762492 | Cell-to-cell propagation of infectious cytosolic protein aggregates |
| Q37196437 | Circadian clocks and neurodegenerative diseases: time to aggregate? |
| Q37619917 | Clustering of tau-immunoreactive pathology in chronic traumatic encephalopathy |
| Q40992216 | Comparative quantitative study of 'signature' pathological lesions in the hippocampus and adjacent gyri of 12 neurodegenerative disorders |
| Q47647268 | Comparison of the in vivo induction and transmission of α-synuclein pathology by mutant α-synuclein fibril seeds in transgenic mice |
| Q43106197 | Conformation determines the seeding potencies of native and recombinant Tau aggregates |
| Q34630618 | Considerations for animal models of blast-related traumatic brain injury and chronic traumatic encephalopathy |
| Q37691525 | Context dependence of protein misfolding and structural strains in neurodegenerative diseases. |
| Q36286068 | Corruption and spread of pathogenic proteins in neurodegenerative diseases |
| Q34283467 | Cytoplasmic retention of protein phosphatase 2A inhibitor 2 (I2PP2A) induces Alzheimer-like abnormal hyperphosphorylation of Tau. |
| Q89736135 | Differences Between Human and Murine Tau at the N-terminal End |
| Q37392690 | Different molecular pathologies result in similar spatial patterns of cellular inclusions in neurodegenerative disease: a comparative study of eight disorders |
| Q36063245 | Distribution of α-synuclein in the spinal cord and dorsal root ganglia in an autopsy cohort of elderly persons |
| Q38195215 | Disturbance of endoplasmic reticulum proteostasis in neurodegenerative diseases |
| Q34027672 | Docosahexaenoic acid signalolipidomics in nutrition: significance in aging, neuroinflammation, macular degeneration, Alzheimer's, and other neurodegenerative diseases |
| Q21135583 | Docosahexaenoic acid-derived neuroprotectin D1 induces neuronal survival via secretase- and PPARγ-mediated mechanisms in Alzheimer's disease models |
| Q28088777 | Drosophila as an In Vivo Model for Human Neurodegenerative Disease |
| Q35266392 | E46K human alpha-synuclein transgenic mice develop Lewy-like and tau pathology associated with age-dependent, detrimental motor impairment |
| Q93377121 | ER Stress, CREB, and Memory: A Tangled Emerging Link in Disease |
| Q92631070 | Emerging Developments in Targeting Proteotoxicity in Neurodegenerative Diseases |
| Q38079242 | Exosomes-associated neurodegeneration and progression of Parkinson's disease |
| Q38138606 | Exosomes: the future of biomarkers in medicine |
| Q36414413 | Exposure to ALS-FTD-CSF generates TDP-43 aggregates in glioblastoma cells through exosomes and TNTs-like structure. |
| Q41594823 | Extracellular Tau Oligomers Induce Invasion of Endogenous Tau into the Somatodendritic Compartment and Axonal Transport Dysfunction |
| Q35924477 | Extracellular membrane vesicles and immune regulation in the brain |
| Q39062953 | Extracellular monomeric tau protein is sufficient to initiate the spread of tau protein pathology |
| Q48395274 | FRET and Flow Cytometry Assays to Measure Proteopathic Seeding Activity in Biological Samples |
| Q37572454 | Factors determining disease duration in Alzheimer's disease: a postmortem study of 103 cases using the Kaplan-Meier estimator and Cox regression |
| Q38345753 | From nucleation to widespread propagation: A prion-like concept for ALS. |
| Q92492331 | From the Entorhinal Region via the Prosubiculum to the Dentate Fascia: Alzheimer Disease-Related Neurofibrillary Changes in the Temporal Allocortex |
| Q35886739 | Frontal cortex neuropathology in dementia pugilistica |
| Q37987142 | Frontotemporal dementia: implications for understanding Alzheimer disease |
| Q34348780 | Gaucher disease and parkinsonism, a molecular link theory |
| Q37951515 | Generalization of the prion hypothesis to other neurodegenerative diseases: an imperfect fit. |
| Q37627211 | Generation of Reactive Oxygen Species (ROS) and Pro-Inflammatory Signaling in Human Brain Cells in Primary Culture |
| Q38621484 | Genetic human prion disease modelled in PrP transgenic Drosophila. |
| Q35169246 | Genetic players in multiple system atrophy: unfolding the nature of the beast |
| Q90399598 | Gut Inflammation in Association With Pathogenesis of Parkinson's Disease |
| Q38620932 | Hierarchical Distribution of the Tau Cytoskeletal Pathology in the Thalamus of Alzheimer's Disease Patients. |
| Q34430288 | Human P301L-mutant tau expression in mouse entorhinal-hippocampal network causes tau aggregation and presynaptic pathology but no cognitive deficits |
| Q38075119 | Human prion diseases: molecular, cellular and population biology |
| Q27322062 | Human-to-mouse prion-like propagation of mutant huntingtin protein |
| Q39193175 | Huntington's disease (HD): the neuropathology of a multisystem neurodegenerative disorder of the human brain. |
| Q35644063 | Hyperphosphorylated tau in young and middle-aged subjects |
| Q90707599 | Icariin Ameliorates Amyloid Pathologies by Maintaining Homeostasis of Autophagic Systems in Aβ1-42-Injected Rats |
| Q38079317 | Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies |
| Q35065979 | Induction of intracellular tau aggregation is promoted by α-synuclein seeds and provides novel insights into the hyperphosphorylation of tau. |
| Q38119873 | Integrating pathways of Parkinson's disease in a molecular interaction map. |
| Q37969262 | Interaction between pathogenic proteins in neurodegenerative disorders |
| Q53324250 | Interaction between α-synuclein and other proteins in neurodegenerative disorders. |
| Q33735667 | Intrastriatal injection of α-synuclein can lead to widespread synucleinopathy independent of neuroanatomic connectivity |
| Q38268519 | Invited review: Prion-like transmission and spreading of tau pathology |
| Q48323738 | Is multiple system atrophy an infectious disease? |
| Q38826332 | Key Points Concerning Amyloid Infectivity and Prion-Like Neuronal Invasion |
| Q36417377 | Laminar distribution of the pathological changes in sporadic frontotemporal lobar degeneration with transactive response (TAR) DNA-binding protein of 43 kDa (TDP-43) proteinopathy: a quantitative study using polynomial curve fitting |
| Q38003064 | Lewy pathology and neurodegeneration in premotor Parkinson's disease |
| Q38136055 | Life cycle of cytosolic prions |
| Q41643603 | Localizing Sources of Brain Disease Progression with Network Diffusion Model |
| Q45754303 | Longitudinal changes of outcome measures in spinal and bulbar muscular atrophy |
| Q38128456 | Loss of functional alpha-synuclein: a toxic event in Parkinson's disease? |
| Q36336839 | Loss of parkin promotes lipid rafts-dependent endocytosis through accumulating caveolin-1: implications for Parkinson's disease |
| Q38746445 | Mapping Neurodegenerative Disease Onset and Progression |
| Q49477647 | Mathematical Modeling of Protein Misfolding Mechanisms in Neurological Diseases: A Historical Overview |
| Q90232431 | Microbiome Influence in the Pathogenesis of Prion and Alzheimer's Diseases |
| Q38849169 | Mitochondrial impairment and oxidative stress compromise autophagosomal degradation of α-synuclein in oligodendroglial cells |
| Q34631209 | Models of β-amyloid induced Tau-pathology: the long and "folded" road to understand the mechanism |
| Q26748105 | Molecular Mechanisms in the Pathogenesis of Alzheimer's disease and Tauopathies-Prion-Like Seeded Aggregation and Phosphorylation |
| Q38038121 | Molecular chaperones, α-synuclein, and neurodegeneration |
| Q38088738 | Molecular diagnosis of human prion disease |
| Q38303573 | Multiple system atrophy: genetic or epigenetic? |
| Q26747418 | NMR Meets Tau: Insights into Its Function and Pathology |
| Q36374952 | Neuron-to-neuron transmission of α-synuclein fibrils through axonal transport |
| Q48624391 | Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer's disease |
| Q37693339 | Neuropathological Staging of Brain Pathology in Sporadic Parkinson's disease: Separating the Wheat from the Chaff |
| Q37955871 | Neuropathology of sporadic Parkinson's disease: evaluation and changes of concepts |
| Q33853865 | Neuroprotectin D1 induces neuronal survival and downregulation of amyloidogenic processing in Alzheimer's disease cellular models |
| Q37876156 | New insights into atypical parkinsonism. |
| Q90289746 | Normal and Pathological Tau Uptake Mediated by M1/M3 Muscarinic Receptors Promotes Opposite Neuronal Changes |
| Q38533327 | Oculo-visual changes and clinical considerations affecting older patients with dementia |
| Q38794219 | Oligomeropathies and pathogenesis of Alzheimer and Parkinson's diseases. |
| Q39064365 | Oxidative stress promotes uptake, accumulation, and oligomerization of extracellular α-synuclein in oligodendrocytes |
| Q98184349 | Parkinson disease and the gut: new insights into pathogenesis and clinical relevance |
| Q94371699 | Parkinson's disease |
| Q38128462 | Parkinson's disease--the debate on the clinical phenomenology, aetiology, pathology and pathogenesis |
| Q35204878 | Passive immunotherapy of tauopathy targeting pSer413-tau: a pilot study in mice |
| Q84590188 | Pathogenesis of the tauopathies |
| Q26850298 | Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders |
| Q48379137 | Phosphorylation at Ser8 as an Intrinsic Regulatory Switch to Regulate the Morphologies and Structures of Alzheimer's 40-residue β-Amyloid (Aβ40) Fibrils |
| Q37419169 | Phosphorylation induces distinct alpha-synuclein strain formation |
| Q38803419 | Phosphorylation of TAR DNA-binding Protein of 43 kDa (TDP-43) by Truncated Casein Kinase 1δ Triggers Mislocalization and Accumulation of TDP-43. |
| Q59099056 | Physiological and pathological functions of LRRK2: implications from substrate proteins |
| Q38942540 | Potential Pathways of Abnormal Tau and α-Synuclein Dissemination in Sporadic Alzheimer's and Parkinson's Diseases |
| Q36076343 | Potential contribution of exosomes to the prion-like propagation of lesions in Alzheimer's disease |
| Q36484091 | Precortical Phase of Alzheimer's Disease (AD)-Related Tau Cytoskeletal Pathology |
| Q91637190 | Prion-Like Mechanisms in Parkinson's Disease |
| Q43936085 | Prion-induced toxicity in PrP transgenic Drosophila |
| Q55380956 | Prion-like Domains in Eukaryotic Viruses. |
| Q38248883 | Prion-like mechanisms in the pathogenesis of tauopathies and synucleinopathies |
| Q38922025 | Prion-like propagation as a pathogenic principle in frontotemporal dementia. |
| Q54263747 | Prion-like protein aggregates exploit the RHO GTPase to cofilin-1 signaling pathway to enter cells. |
| Q38166717 | Prions Ex Vivo: What Cell Culture Models Tell Us about Infectious Proteins |
| Q89803861 | Protein Structure and Biology: Poster Abstracts |
| Q27005843 | Proteolytic clearance of extracellular α-synuclein as a new therapeutic approach against Parkinson disease |
| Q36127050 | Proteolytic cleavage of extracellular α-synuclein by plasmin: implications for Parkinson disease |
| Q39433741 | Proteostasis of tau. Tau overexpression results in its secretion via membrane vesicles. |
| Q99637837 | Putative dendritic correlates of chronic traumatic encephalopathy: A preliminary quantitative Golgi exploration |
| Q39556052 | Rapid cell-surface prion protein conversion revealed using a novel cell system |
| Q58720864 | Rapid dissemination of alpha-synuclein seeds through neural circuits in an in-vivo prion-like seeding experiment |
| Q64071650 | Rescue of degenerating neurons and cells by stem cell released molecules: using a physiological renormalization strategy |
| Q37821048 | Rescuing neurons in prion disease |
| Q37990996 | Review: Creutzfeldt-Jakob disease: prion protein type, disease phenotype and agent strain. |
| Q38667942 | Review: Sporadic Parkinson's disease: development and distribution of α-synuclein pathology |
| Q34869120 | Seeding of normal Tau by pathological Tau conformers drives pathogenesis of Alzheimer-like tangles |
| Q34801378 | Sequence-dependent internalization of aggregating peptides |
| Q33852825 | Single mutations in tau modulate the populations of fibril conformers through seed selection |
| Q46164744 | Single-molecule assays for investigating protein misfolding and aggregation |
| Q48303426 | Skin biomarkers for neurodegenerative disease: a future perspective. |
| Q51121904 | Solving the conundrum of insoluble protein aggregates. |
| Q35421505 | Spatial patterns of FUS-immunoreactive neuronal cytoplasmic inclusions (NCI) in neuronal intermediate filament inclusion disease (NIFID). |
| Q48617876 | Spatial patterns of the tau pathology in progressive supranuclear palsy |
| Q36054214 | Stimulation of autophagy reduces neurodegeneration in a mouse model of human tauopathy |
| Q35682515 | Studies of protein aggregation in A53T α-synuclein transgenic, Tg2576 transgenic, and P246L presenilin-1 knock-in cross bred mice. |
| Q38210018 | Studies of protein folding and dynamics using single molecule fluorescence spectroscopy. |
| Q36341144 | Suppression of dynamin GTPase decreases α-synuclein uptake by neuronal and oligodendroglial cells: a potent therapeutic target for synucleinopathy |
| Q38059684 | Synucleins: are they two-edged swords? |
| Q48347173 | TDP-43 Prions |
| Q38760024 | Targeting autophagy as a strategy for drug discovery and therapeutic modulation |
| Q37069517 | Tau accumulation activates the unfolded protein response by impairing endoplasmic reticulum-associated degradation |
| Q42151546 | Tau and caspase 3 as targets for neuroprotection |
| Q55405326 | Tau seeding activity begins in the transentorhinal/entorhinal regions and anticipates phospho-tau pathology in Alzheimer's disease and PART. |
| Q35622023 | Templated misfolding of Tau by prion-like seeding along neuronal connections impairs neuronal network function and associated behavioral outcomes in Tau transgenic mice |
| Q39410246 | The Endoplasmic Reticulum Unfolded Protein Response in Neurodegenerative Disorders and Its Potential Therapeutic Significance |
| Q47102449 | The Evidence for the Spread and Seeding Capacities of the Mutant Huntingtin Protein in in Vitro Systems and Their Therapeutic Implications |
| Q52689033 | The Pathoconnectivity Profile of Alzheimer's Disease: A Morphometric Coalteration Network Analysis. |
| Q39035488 | The Prion-Like Behavior of Assembled Tau in Transgenic Mice |
| Q47199216 | The Role Of The Prion Protein In The Internalization Of α-Synuclein Amyloids |
| Q57051340 | The Synergy of Aging and LPS Exposure in a Mouse Model of Parkinson's Disease |
| Q28254943 | The Ubiquitin-Proteasome System and Molecular Chaperone Deregulation in Alzheimer's Disease |
| Q37994283 | The amyloid state of proteins in human diseases |
| Q35427654 | The brainstem pathologies of Parkinson's disease and dementia with Lewy bodies. |
| Q37989099 | The contribution of different prion protein types and host polymorphisms to clinicopathological variations in Creutzfeldt-Jakob disease |
| Q39211074 | The double life of the ribosome: When its protein folding activity supports prion propagation |
| Q38168592 | The fate of cell grafts for the treatment of Huntington's disease: the post-mortem evidence. |
| Q34054680 | The intersection of amyloid beta and tau at synapses in Alzheimer's disease |
| Q47651840 | The morphometric co-atrophy networking of schizophrenia, autistic and obsessive spectrum disorders |
| Q28083428 | The preclinical phase of the pathological process underlying sporadic Alzheimer's disease |
| Q95650650 | The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges |
| Q34263380 | The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease. |
| Q28535404 | The toll-like receptor agonist imiquimod is active against prions |
| Q89973008 | Thiol-mediated and catecholamine-enhanced multimerization of a cerebrovascular disease enriched fragment of NOTCH3 |
| Q41713209 | Three- and four-repeat Tau coassemble into heterogeneous filaments: an implication for Alzheimer disease |
| Q57838382 | Transcellular Spreading of Tau in Tauopathies |
| Q57805726 | Tryptophan 32-mediated SOD1 aggregation is attenuated by pyrimidine-like compounds in living cells |
| Q84127203 | Variably protease-sensitive prionopathy: a novel disease of the prion protein |
| Q38935142 | Visual signs and symptoms of corticobasal degeneration |
| Q84489164 | [Gastrointestinal dysfunction in idiopathic Parkinson's disease] |
| Q86424124 | [Pathogenesis and prevention of Alzheimer's disease: when and in what way does the pathological process begin?] |
| Q38039369 | α-Synuclein and neuronal cell death |
| Q36718306 | α-Synuclein oligomers and clinical implications for Parkinson disease |
| Q24633663 | α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells |
| Q41681113 | α-Synuclein strains cause distinct synucleinopathies after local and systemic administration |
| Q38912683 | α-Synuclein-carrying extracellular vesicles in Parkinson's disease: deadly transmitters |
Search more.